Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report sent to investors on Monday morning. The firm issued a sell rating on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, March 18th.

Can-Fite BioPharma Trading Up 8.6 %

Shares of CANF stock opened at $1.52 on Monday. The stock has a market capitalization of $5.38 million, a P/E ratio of -0.85 and a beta of 1.12. The firm’s 50 day moving average is $1.58 and its 200 day moving average is $1.82. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers boosted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 26,880 shares of the company’s stock after acquiring an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter. 21.00% of the stock is owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.